TENET HEALTHCARE CORP (THC) Fundamental Analysis & Valuation

NYSE:THC • US88033G4073

Current stock price

194.6 USD
+4.32 (+2.27%)
At close:
194.6 USD
0 (0%)
After Hours:

This THC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. THC Profitability Analysis

1.1 Basic Checks

  • In the past year THC was profitable.
  • THC had a positive operating cash flow in the past year.
  • In the past 5 years THC has always been profitable.
  • In the past 5 years THC always reported a positive cash flow from operatings.
THC Yearly Net Income VS EBIT VS OCF VS FCFTHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

1.2 Ratios

  • With a decent Return On Assets value of 4.74%, THC is doing good in the industry, outperforming 74.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 33.34%, THC belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
  • THC has a Return On Invested Capital of 12.14%. This is amongst the best in the industry. THC outperforms 86.00% of its industry peers.
  • THC had an Average Return On Invested Capital over the past 3 years of 10.81%. This is above the industry average of 8.63%.
  • The 3 year average ROIC (10.81%) for THC is below the current ROIC(12.14%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.74%
ROE 33.34%
ROIC 12.14%
ROA(3y)5.99%
ROA(5y)4.56%
ROE(3y)49.35%
ROE(5y)54.59%
ROIC(3y)10.81%
ROIC(5y)9.72%
THC Yearly ROA, ROE, ROICTHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • THC's Profit Margin of 6.60% is amongst the best of the industry. THC outperforms 83.00% of its industry peers.
  • In the last couple of years the Profit Margin of THC has grown nicely.
  • THC has a Operating Margin of 17.74%. This is amongst the best in the industry. THC outperforms 95.00% of its industry peers.
  • THC's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 82.26%, THC belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of THC has remained more or less at the same level.
Industry RankSector Rank
OM 17.74%
PM (TTM) 6.6%
GM 82.26%
OM growth 3Y14.14%
OM growth 5Y19.99%
PM growth 3Y45.5%
PM growth 5Y23.89%
GM growth 3Y-0.27%
GM growth 5Y-0.2%
THC Yearly Profit, Operating, Gross MarginsTHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. THC Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so THC is still creating some value.
  • The number of shares outstanding for THC has been reduced compared to 1 year ago.
  • The number of shares outstanding for THC has been reduced compared to 5 years ago.
  • Compared to 1 year ago, THC has an improved debt to assets ratio.
THC Yearly Shares OutstandingTHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
THC Yearly Total Debt VS Total AssetsTHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 1.87 indicates that THC is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • THC has a Altman-Z score of 1.87. This is comparable to the rest of the industry: THC outperforms 46.00% of its industry peers.
  • The Debt to FCF ratio of THC is 5.21, which is a neutral value as it means it would take THC, 5.21 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 5.21, THC is in line with its industry, outperforming 59.00% of the companies in the same industry.
  • THC has a Debt/Equity ratio of 3.10. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 3.10, THC is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.1
Debt/FCF 5.21
Altman-Z 1.87
ROIC/WACC1.39
WACC8.72%
THC Yearly LT Debt VS Equity VS FCFTHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • THC has a Current Ratio of 1.76. This is a normal value and indicates that THC is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of THC (1.76) is better than 72.00% of its industry peers.
  • THC has a Quick Ratio of 1.68. This is a normal value and indicates that THC is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 1.68, THC is doing good in the industry, outperforming 71.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.68
THC Yearly Current Assets VS Current LiabilitesTHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. THC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.01% over the past year.
  • THC shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.26% yearly.
  • Looking at the last year, THC shows a small growth in Revenue. The Revenue has grown by 3.12% in the last year.
  • Measured over the past years, THC shows a small growth in Revenue. The Revenue has been growing by 3.85% on average per year.
EPS 1Y (TTM)41.01%
EPS 3Y34.93%
EPS 5Y16.26%
EPS Q2Q%36.63%
Revenue 1Y (TTM)3.12%
Revenue growth 3Y3.58%
Revenue growth 5Y3.85%
Sales Q2Q%8.97%

3.2 Future

  • THC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.61% yearly.
  • The Revenue is expected to grow by 4.13% on average over the next years.
EPS Next Y2.23%
EPS Next 2Y3.05%
EPS Next 3Y7.17%
EPS Next 5Y3.61%
Revenue Next Year3.5%
Revenue Next 2Y2.69%
Revenue Next 3Y3.67%
Revenue Next 5Y4.13%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
THC Yearly Revenue VS EstimatesTHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B 25B
THC Yearly EPS VS EstimatesTHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

8

4. THC Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.60 indicates a reasonable valuation of THC.
  • Based on the Price/Earnings ratio, THC is valued cheaply inside the industry as 87.00% of the companies are valued more expensively.
  • THC is valuated cheaply when we compare the Price/Earnings ratio to 26.21, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 11.34, the valuation of THC can be described as reasonable.
  • THC's Price/Forward Earnings ratio is rather cheap when compared to the industry. THC is cheaper than 87.00% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of THC to the average of the S&P500 Index (23.13), we can say THC is valued rather cheaply.
Industry RankSector Rank
PE 11.6
Fwd PE 11.34
THC Price Earnings VS Forward Price EarningsTHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 92.00% of the companies in the same industry are more expensive than THC, based on the Enterprise Value to EBITDA ratio.
  • 91.00% of the companies in the same industry are more expensive than THC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.69
EV/EBITDA 5.78
THC Per share dataTHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates THC does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of THC may justify a higher PE ratio.
PEG (NY)5.21
PEG (5Y)0.71
EPS Next 2Y3.05%
EPS Next 3Y7.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. THC Dividend Analysis

5.1 Amount

  • No dividends for THC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

THC Fundamentals: All Metrics, Ratios and Statistics

TENET HEALTHCARE CORP

NYSE:THC (4/7/2026, 5:05:00 PM)

After market: 194.6 0 (0%)

194.6

+4.32 (+2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-11
Earnings (Next)04-30
Inst Owners98.76%
Inst Owner Change0%
Ins Owners1.16%
Ins Owner Change3.82%
Market Cap16.92B
Revenue(TTM)21.31B
Net Income(TTM)1.41B
Analysts81.43
Price Target258.22 (32.69%)
Short Float %2.89%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.87%
Min EPS beat(2)10.92%
Max EPS beat(2)14.82%
EPS beat(4)4
Avg EPS beat(4)25.53%
Min EPS beat(4)10.92%
Max EPS beat(4)38.59%
EPS beat(8)8
Avg EPS beat(8)35.38%
EPS beat(12)12
Avg EPS beat(12)33.64%
EPS beat(16)16
Avg EPS beat(16)40.61%
Revenue beat(2)0
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)0%
Revenue beat(4)2
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.28%
Max Revenue beat(4)1.13%
Revenue beat(8)5
Avg Revenue beat(8)0.39%
Revenue beat(12)8
Avg Revenue beat(12)0.73%
Revenue beat(16)9
Avg Revenue beat(16)0.21%
PT rev (1m)1.13%
PT rev (3m)8.08%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-5.94%
EPS NY rev (1m)0%
EPS NY rev (3m)2.98%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.85%
Valuation
Industry RankSector Rank
PE 11.6
Fwd PE 11.34
P/S 0.79
P/FCF 6.69
P/OCF 4.78
P/B 4.01
P/tB N/A
EV/EBITDA 5.78
EPS(TTM)16.78
EY8.62%
EPS(NY)17.15
Fwd EY8.81%
FCF(TTM)29.09
FCFY14.95%
OCF(TTM)40.71
OCFY20.92%
SpS245.06
BVpS48.53
TBVpS-95.75
PEG (NY)5.21
PEG (5Y)0.71
Graham Number135.36
Profitability
Industry RankSector Rank
ROA 4.74%
ROE 33.34%
ROCE 14.99%
ROIC 12.14%
ROICexc 13.71%
ROICexgc 31.29%
OM 17.74%
PM (TTM) 6.6%
GM 82.26%
FCFM 11.87%
ROA(3y)5.99%
ROA(5y)4.56%
ROE(3y)49.35%
ROE(5y)54.59%
ROIC(3y)10.81%
ROIC(5y)9.72%
ROICexc(3y)12%
ROICexc(5y)10.68%
ROICexgc(3y)26.71%
ROICexgc(5y)23.47%
ROCE(3y)13.34%
ROCE(5y)12%
ROICexgc growth 3Y20.18%
ROICexgc growth 5Y23.63%
ROICexc growth 3Y17.33%
ROICexc growth 5Y21.67%
OM growth 3Y14.14%
OM growth 5Y19.99%
PM growth 3Y45.5%
PM growth 5Y23.89%
GM growth 3Y-0.27%
GM growth 5Y-0.2%
F-Score6
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 3.1
Debt/FCF 5.21
Debt/EBITDA 2.82
Cap/Depr 117.03%
Cap/Sales 4.74%
Interest Coverage 4.37
Cash Conversion 76.24%
Profit Quality 179.82%
Current Ratio 1.76
Quick Ratio 1.68
Altman-Z 1.87
F-Score6
WACC8.72%
ROIC/WACC1.39
Cap/Depr(3y)105.72%
Cap/Depr(5y)96.95%
Cap/Sales(3y)4.3%
Cap/Sales(5y)4.05%
Profit Quality(3y)160.11%
Profit Quality(5y)131.6%
High Growth Momentum
Growth
EPS 1Y (TTM)41.01%
EPS 3Y34.93%
EPS 5Y16.26%
EPS Q2Q%36.63%
EPS Next Y2.23%
EPS Next 2Y3.05%
EPS Next 3Y7.17%
EPS Next 5Y3.61%
Revenue 1Y (TTM)3.12%
Revenue growth 3Y3.58%
Revenue growth 5Y3.85%
Sales Q2Q%8.97%
Revenue Next Year3.5%
Revenue Next 2Y2.69%
Revenue Next 3Y3.67%
Revenue Next 5Y4.13%
EBIT growth 1Y17.54%
EBIT growth 3Y18.23%
EBIT growth 5Y24.61%
EBIT Next Year24.61%
EBIT Next 3Y10.68%
EBIT Next 5Y7.95%
FCF growth 1Y126.7%
FCF growth 3Y99.01%
FCF growth 5Y-2.47%
OCF growth 1Y72.94%
OCF growth 3Y48.41%
OCF growth 5Y0.77%

TENET HEALTHCARE CORP / THC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TENET HEALTHCARE CORP (THC) stock?

ChartMill assigns a fundamental rating of 6 / 10 to THC.


Can you provide the valuation status for TENET HEALTHCARE CORP?

ChartMill assigns a valuation rating of 8 / 10 to TENET HEALTHCARE CORP (THC). This can be considered as Undervalued.


What is the profitability of THC stock?

TENET HEALTHCARE CORP (THC) has a profitability rating of 9 / 10.


How financially healthy is TENET HEALTHCARE CORP?

The financial health rating of TENET HEALTHCARE CORP (THC) is 5 / 10.


Is the dividend of TENET HEALTHCARE CORP sustainable?

The dividend rating of TENET HEALTHCARE CORP (THC) is 0 / 10 and the dividend payout ratio is 0%.